LONDON, Dec. 20, 2013 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake" or the "Company") (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, today issued a letter by Chief Executive Officer Dr. Roger Crystal updating shareholders on the Company's progress in 2013.
Dear Fellow Shareholders,
As the executive management team of Lightlake Therapeutics Inc. looks ahead to 2014, we are encouraged by our hard work and progress in 2013 and are eager for the opportunities and advancements that 2014 should bring to our company. This has been a fruitful year for the Company as we have achieved a number of milestones, both operationally and clinically. We continue to work diligently to advance our clinical pipeline and secure our patent portfolio as we focus on bringing an intranasal naloxone treatment to market to reverse opioid overdoses.
Since our last update in April 2013, we would like to highlight a few of our accomplishments. We recently completed a two-week joint clinical study with the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), for opioid overdose. We received the initial data from this study and it has shown that our naloxone nasal spray can potentially be delivered into the blood stream at least as quickly as the injection process currently used by hospitals, first responders, and others treating opioid overdoses.
The data received from this study will also allow us to apply our novel method of naloxone delivery into a wider range of various addictions that are currently affecting millions of people on a daily basis. While opioid overdose is a significant, near-term opportunity that can potentially be treated with an intranasal naloxone application, there are a number of other markets that our application could potentially be app
|SOURCE Lightlake Therapeutics Inc.|
Copyright©2012 PR Newswire.
All rights reserved